Selective small molecule PARG inhibitor causes replication fork stalling and cancer cell death [PDF]
, 2019 al., et +4 more
core +1 more source
Role of poly(ADP-ribosyl)ation in a 'two-hit' model of hypoxia and oxidative stress in human A549 epithelial cells in vitro [PDF]
, 2017 Erdélyi, Katalin +3 more
core +1 more source
Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis. [PDF]
J Clin OncolFallah J +12 more
europepmc +1 more source
Related searches:
Comparative Analyses of Poly(ADP-Ribose) Polymerase Inhibitors
International Journal of Toxicology, 2022Poly(ADP-ribose) polymerase inhibitors (PARPi) are approved as monotherapies in BRCA1/2-mutated (m BRCA1/2) metastatic breast and ovarian cancers, and in advanced pancreatic and metastatic castration-resistant prostate cancers. Differential safety profiles across PARPi necessitate improved mechanistic understanding of inhibitor differences, especially
Mausumee Guha +9 more
openaire +2 more sources
Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy
The Cancer Journal, 2021Abstract The introduction of poly(ADP-ribose) polymerase (PARP) inhibitors has led to significant improvements in outcome for several cancer types, most notably high-grade serous ovarian cancer. However, in general, benefit is restricted to tumors characterized by either BRCA1/2 mutation or homologous recombination deficiency.
openaire +2 more sources
Poly(ADP-Ribose) Polymerase Inhibitors
Current Medicinal Chemistry, 2003Poly(ADP-ribose) polymerase-1 (PARP-1) is the principal member of the PARP enzyme family consisting of PARP-1 and several recently identified novel poly(ADP-ribosyl)ating enzymes. PARP-1 functions as a DNA damage sensor and signalling molecule. Upon binding to DNA breaks, activated PARP cleaves NAD(+) into nicotinamide and ADP-ribose and polymerizes ...
Garry J, Southan, Csaba, Szabó
openaire +2 more sources
Novel poly(ADP-ribose) polymerase-1 inhibitors
Bioorganic & Medicinal Chemistry Letters, 2007Synthesis and activity of a series of 3-aroyl-derived analogs of novel pyrrolocarbazole 1 as poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors are disclosed.
Derek, Dunn +3 more
openaire +3 more sources
Natural Inhibitors of Poly(ADP-ribose) Polymerase-1
Molecular Neurobiology, 2012Poly(ADP-ribose) polymerases (PARPs) are enzymes that catalyze the transfer of ADP-ribose units from β-nicotinamide adenine dinucleotide (NAD(+)) to acceptor proteins. PARP-1 is responsible for more than 90 % of protein poly-ADP-ribosylation in the brain and may play a role as a molecular switch for cell survival and death. The functional roles of PARP-
Marek, Banasik +2 more
openaire +2 more sources
Poly (ADP-ribose) Polymerase Inhibitors in Cancer Treatment
American Journal of Clinical Oncology, 2014Recent research on inhibitors of poly (ADP-ribose) polymerase (PARP) has demonstrated their potential for improving cancer therapy. They inhibit protein poly (ADP-ribosyl)ation and thus affect numerous molecular and cellular functions, including DNA repair and cell survival, that are critical for such physiological and patho-physiological states as ...
Kathryn A, Mason +5 more
openaire +2 more sources
Purpose of review In the past few years, the advent of PARP inhibitors has been a revolution in the management of ovarian cancer. Patients harboring somatic or germ line BRCA1/2 mutations exhibit different clinical and treatment response behavior.
Hélène, Vanacker +2 more
openaire +2 more sources